| Immune‐related adverse events as a biomarker in non‐melanoma patients treated with programmed cell death 1 inhibitors J Judd, M Zibelman, E Handorf, J O'Neill, C Ramamurthy, S Bentota, ... The oncologist 22 (10), 1232-1237, 2017 | 128 | 2017 |
| Emerging role of immunotherapy in urothelial carcinoma—advanced disease M Zibelman, C Ramamurthy, ER Plimack Urologic Oncology: Seminars and Original Investigations 34 (12), 538-547, 2016 | 55 | 2016 |
| Impact of tumor microenvironment composition on therapeutic responses and clinical outcomes in cancer F Anari, C Ramamurthy, M Zibelman Future Oncology 14 (14), 1409-1421, 2018 | 50 | 2018 |
| Hippocampal volumes in patients with chronic combat-related posttraumatic stress disorder: a systematic review JE Childress, EJ McDowell, VVK Dalai, SR Bogale, C Ramamurthy, ... The Journal of neuropsychiatry and clinical neurosciences 25 (1), 12-25, 2013 | 50 | 2013 |
| LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible … JE Rosenberg, M Milowsky, C Ramamurthy, N Mar, RR McKay, ... Annals of Oncology 33, S1441, 2022 | 48 | 2022 |
| Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer C Ramamurthy, EA Handorf, AF Correa, JR Beck, DM Geynisman Urologic Oncology: Seminars and Original Investigations 37 (10), 688-695, 2019 | 40 | 2019 |
| TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after … P Grivas, D Pouessel, CH Park, P Barthélémy, M Bupathi, DP Petrylak, ... Journal of Clinical Oncology 40 (6_suppl), 434-434, 2022 | 36 | 2022 |
| Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer PH O'Donnell, MI Milowsky, DP Petrylak, CJ Hoimes, TW Flaig, N Mar, ... Journal of Clinical Oncology 41 (25), 4107-4117, 2023 | 35 | 2023 |
| Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study N Ji, N Mukherjee, RM Reyes, J Gelfond, M Javors, JJ Meeks, ... Journal for immunotherapy of cancer 9 (3), 2021 | 23 | 2021 |
| Managing adverse effects of immunotherapy JN Gerson, C Ramamurthy, H Borghaei Clin Adv Hematol Oncol 16 (5), 364-374, 2018 | 22 | 2018 |
| A decade of robotic-assisted radical nephrectomy with inferior vena cava thrombectomy: a systematic review and meta-analysis of perioperative outcomes H Garg, SP Psutka, AA Hakimi, HL Kim, AM Mansour, DK Pruthi, MA Liss, ... The Journal of urology 208 (3), 542-560, 2022 | 20 | 2022 |
| Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior … DP Petrylak, ST Tagawa, RK Jain, M Bupathi, AV Balar, A Rezazadeh, ... Journal of Clinical Oncology 38 (15_suppl), 5027-5027, 2020 | 18 | 2020 |
| Immune checkpoint inhibitor therapy: what line of therapy and how to choose? C Ramamurthy, JL Godwin, H Borghaei Current Treatment Options in Oncology 18, 1-14, 2017 | 15 | 2017 |
| Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that … DP Petrylak, ST Tagawa, RK Jain, M Bupathi, AV Balar, A Rezazadeh, ... Journal of Clinical Oncology 41 (6_suppl), 520-520, 2023 | 12 | 2023 |
| Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral … M Cajipe, H Wang, A Elshabrawy, D Kaushik, M Liss, R Svatek, S Wu, ... Urologic Oncology: Seminars and Original Investigations 38 (4), 231-239, 2020 | 12 | 2020 |
| Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial … P Grivas, D Pouessel, CH Park, P Barthelemy, M Bupathi, DP Petrylak, ... Journal of Clinical Oncology 41 (6_suppl), 518-518, 2023 | 9 | 2023 |
| Randomized controlled trials in hereditary cancer syndromes C Ramamurthy, Y Chertock, MJ Hall Surgical Oncology Clinics 26 (4), 729-750, 2017 | 7 | 2017 |
| Enfortumab vedotin (EV) alone or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial … PH O'Donnell, JE Rosenberg, CJ Hoimes, DP Petrylak, MI Milowsky, ... Journal of Clinical Oncology 41 (6_suppl), 499-499, 2023 | 6 | 2023 |
| Hereditary cancer gene variants in hispanic men with a personal or family history of prostate cancer C Ramamurthy, EW Stutz, M Goros, J Gelfond, TL Johnson-Pais, ... Clinical Genitourinary Cancer 20 (3), 237-243, 2022 | 5 | 2022 |
| Disparities in cancer genetic testing and variants of uncertain significance in the Hispanic population of South Texas S Soewito, R Wyatt, E Berenson, N Poullard, S Gessay, L Mette, E Marin, ... JCO Oncology Practice 18 (5), e805-e813, 2022 | 5 | 2022 |
